Wiseheart MedVal completes ￥100M+ Series A financing to accelerate clinical translation of innovative cell therapies for neurological diseases

Recently, Wiseheart MedVal announced the completion of its Series A financing round, raising over 100 million. This round was led by the Beijing Energy Green Fund, managed by Beijing Energy Tongxin Investment under the Beijing Energy Group. The raised funds will be used to advance clinical research on cell therapy products for neurological diseases, further solidifying Wiseheart MedVal's leading position in the field of neurological disease cell therapy and accelerating the translation of innovative achievements into clinical and industrial applications.

Wiseheart MedVal is a national high-tech enterprise dedicated to the research and development of cell therapies for neurological diseases. Leveraging internationally leading induced neural stem cell (iNSC) technology with independent intellectual property rights, Wiseheart MedVal has systematically developed a pipeline of neurological cell therapies targeting major unmet clinical needs, including Parkinson's disease, epilepsy, stroke, and spinal cord injury. This forms a clear and differentiated product portfolio.

Its lead investigational candidate, an iNSC-derived dopaminergic neural precursor cell (iNSC-DAP) injection for the treatment of Parkinson's disease, has completed the longest follow-up of over two years in China's first state-filed clinical study for Parkinson's disease conducted at Xuanwu Hospital of Capital Medical University. The study demonstrated sustained and significant long-term improvements in patients' "on-off" time, MDS-UPDRS scores, and imaging indicators, along with a favorable safety profile, validating the clinical feasibility of this innovative technological approach.

The field of neurological diseases has long faced a lack of effective treatment options, and cell therapy is emerging as a potentially transformative direction with significant clinical value and broad industrial prospects.

Building on a solid foundation of original scientific research and a clear clinical translation pathway, Wiseheart MedVal has achieved internationally influential clinical breakthroughs in areas such as Parkinson's disease, reflecting the company's comprehensive capabilities in technological systems, clinical execution, and long-term strategic planning.